by Jordana Choucair | Nov 18, 2022 | Opioid/Substance Use Disorders
A study published in JAMA Network Open found that individuals with substance use disorders (SUDs) had significant annual declines in SUD-related emergency department use over five years compared with patients who received “usual care.” The study notes that...
by Jordana Choucair | Nov 16, 2022 | Opioid/Substance Use Disorders
The opioid overdose reversal drug naloxone may be safe and effective for over-the-counter use in some forms, the U.S. Food and Drug Administration (FDA) said on Tuesday. The FDA would still require data on individual products from manufacturers for them to be...
by Jordana Choucair | Nov 15, 2022 | Opioid/Substance Use Disorders
Walmart Inc. has agreed to pay $3.1 billion to settle lawsuits brought by states, cities, and Native American tribes over its role in the opioid crisis. However, the company did not admit liability. Walmart’s agreement follows settlements earlier this month from...
by Jordana Choucair | Nov 4, 2022 | Opioid/Substance Use Disorders
The Centers for Disease Control and Prevention (CDC) released updated guidelines that give clinicians more flexibility in the way they prescribe opioids for short- and long-term pain. The new recommendations avoid strict figures on dosage and length of opioid...
by Jordana Choucair | Nov 4, 2022 | Opioid/Substance Use Disorders
New York Attorney General Letitia James announced that Teva Pharmaceuticals will pay the state up to $523 million to settle claims related to its role in fueling the state’s opioid crisis. The funds are part of Teva’s $4 billion-plus global settlement, which...
by Jordana Choucair | Nov 2, 2022 | Opioid/Substance Use Disorders
CVS, Walgreens, and Walmart have tentatively agreed to pay at least $12 billion to settle a number of lawsuits brought by states and local governments alleging the retailers mishandled prescriptions of opioid painkillers. The deal calls for CVS to pay $5 billion,...
Recent Comments